860 related articles for article (PubMed ID: 27339115)
1. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
3. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
Dearnaley D; Syndikus I; Sumo G; Bidmead M; Bloomfield D; Clark C; Gao A; Hassan S; Horwich A; Huddart R; Khoo V; Kirkbride P; Mayles H; Mayles P; Naismith O; Parker C; Patterson H; Russell M; Scrase C; South C; Staffurth J; Hall E
Lancet Oncol; 2012 Jan; 13(1):43-54. PubMed ID: 22169269
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
7. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
8. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
11. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
13. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray J; Griffin C; Gulliford S; Syndikus I; Staffurth J; Panades M; Scrase C; Parker C; Khoo V; Dean J; Mayles H; Mayles P; Thomas S; Naismith O; Baker A; Mossop H; Cruickshank C; Hall E; Dearnaley D;
Radiother Oncol; 2020 Jan; 142():62-71. PubMed ID: 31767473
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
Wilson JM; Dearnaley DP; Syndikus I; Khoo V; Birtle A; Bloomfield D; Choudhury A; Graham J; Ferguson C; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Rimmer Y; Scrase C; Staffurth J; Stockdale A; Cruickshank C; Griffin C; Hall E;
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1179-1189. PubMed ID: 29722660
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
[TBL] [Abstract][Full Text] [Related]
19. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
20. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles CE; Griffin CL; Kirby AM; Titley J; Agrawal RK; Alhasso A; Bhattacharya IS; Brunt AM; Ciurlionis L; Chan C; Donovan EM; Emson MA; Harnett AN; Haviland JS; Hopwood P; Jefford ML; Kaggwa R; Sawyer EJ; Syndikus I; Tsang YM; Wheatley DA; Wilcox M; Yarnold JR; Bliss JM;
Lancet; 2017 Sep; 390(10099):1048-1060. PubMed ID: 28779963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]